ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,583Medicare Part D Prescriptions Filled, Including Refills

Rank: 10 out of 247

$737K Total Retail Price of All Prescriptions

Rank: 10 out of 247

511 Patients Receiving at Least One Drug in Part D
87%Patients 65 Years and Older
52% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maine
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 511 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

9% of this provider’s 511 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 9,914 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$70 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maine
SIMVASTATIN 553 510 1 1
FUROSEMIDE 530 518 2 5
ATORVASTATIN CALCIUM 504 489 3 8
AMLODIPINE BESYLATE 397 378 4 6
LISINOPRIL 348 309 5 2
OMEPRAZOLE 316 298 6 4
LEVOTHYROXINE SODIUM 313 290 7 3
ATENOLOL 300 294 8 10
ALENDRONATE SODIUM 258 252 9 32
CITALOPRAM HBR 245 242 10 20
HYDRALAZINE HCL 227 222 11 99
METFORMIN HCL 194 171 12 12
SPIRIVA 186 174 13 26
METOPROLOL SUCCINATE 185 185 14 14
HYDROCHLOROTHIAZIDE 178 177 15 9
METOPROLOL TARTRATE 168 166 16 7
LOSARTAN POTASSIUM 160 152 17 15
DIOVAN 150 144 18 38
LIPITOR 149 144 19 50
ESCITALOPRAM OXALATE 145 140 20 65
DONEPEZIL HCL 137 137 21 35
CRESTOR 124 109 22 30
FELODIPINE ER 117 117 23 127
WARFARIN SODIUM 114 111 24 13
KLOR-CON M20 111 104 25 44
TRAMADOL HCL 93 90 26 25
FLUTICASONE PROPIONATE 83 76 27 37
GABAPENTIN 81 81 28 17
HYDROCODONE-ACETAMINOPHEN 79 64 S3 29 11
TAMSULOSIN HCL 79 79 29 31
NAMENDA 77 77 31 47
SERTRALINE HCL 77 75 31 16
INSULIN SYRINGE 76 63 33 68
POTASSIUM CHLORIDE 73 69 34 36
ALLOPURINOL 70 68 35 33
DOXAZOSIN MESYLATE 67 63 36 57
PROAIR HFA 66 64 37 29
PREDNISONE 64 62 38 21
PANTOPRAZOLE SODIUM 60 49 39 19
PRAVASTATIN SODIUM 56 50 40 23
FINASTERIDE 56 56 40 73
BENICAR 55 55 42 116
VESICARE 55 55 42 143
NEXIUM 52 52 44 42
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 52 44 51
DILTIAZEM ER 50 50 46 108
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 7, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.